Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL15066370 | 0.98 | CARM1 (0.53) | CARM1PRMT6EPHX1SMN1; SMN2NPC1 | |
| Hydrogen Sulfide SCHEMBL15066150 | 0.98 | CARM1 (0.53) | CARM1PRMT6EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL9679337 | 0.96 | EPHX1 (0.54) | CARM1PRMT6EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL901540 | 0.94 | EPHX1 (0.57) | CARM1PRMT6EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL22393075 | 0.94 | EPHX1 (0.57) | CARM1PRMT6EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL23845320 | 0.94 | EPHX1 (0.57) | CARM1PRMT6EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL901572 | 0.94 | EPHX1 (0.57) | CARM1PRMT6EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL10055063 | 0.91 | CARM1 (0.57) | CARM1PRMT6EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL10055002 | 0.91 | CARM1 (0.57) | CARM1PRMT6EPHX1SMN1; SMN2NPC1 | |
| SCHEMBL18434523 | 0.91 | CARM1 (0.57) | CARM1PRMT6EPHX1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-115362003-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-9238625-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9096515-B2 | Methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2797870-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | Reviva Pharmaceuticals, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140066500-A1 | CYCLOALKYLMETHYLAMINES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140024679-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024709-A1 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8604244-B2 | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| WO-2013102195-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20120172426-A1 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2012003501-A2 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024679-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | CARM1 655/4885PRMT6 384/4885EPHX1 394/4885 |
| US-20140066500-A1 | CYCLOALKYLMETHYLAMINES | PNMT, TPH1, TPH2 | CARM1 799/4885PRMT6 506/4885EPHX1 1661/4885 |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | CARM1 2598/4885PRMT6 1544/4885EPHX1 1840/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | CARM1 2598/4885PRMT6 1544/4885EPHX1 1840/4885 |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | CARM1 2598/4885PRMT6 1544/4885EPHX1 1840/4885 |
| US-20120172426-A1 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives | TPH1, TPH2, PNMT | CARM1 991/4885PRMT6 739/4885EPHX1 1396/4885 |
| US-20140024709-A1 | METHODS OF USING CYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, TPH1, TPH2 | CARM1 972/4885PRMT6 662/4885EPHX1 1502/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | CARM1 2598/4885PRMT6 1544/4885EPHX1 1840/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | CARM1 2598/4885PRMT6 1544/4885EPHX1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.